Compare Cassava Sciences Inc (FLNA) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sherwin-Williams Company (The) Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.34M), while Sherwin-Williams Company (The) Common Stock trades at $325.43 (market cap $78.78B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 2229.2× Cassava Sciences Inc's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SHW | |
|---|---|---|
Market Cap | $35.34M | $78.78B |
Volume | 251,946 | 1,403,311 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $372.60 |
52-Week Low | $0.68 | $293.00 |
Typical Hold Time | 38 Days | — |
Enterprise Value | -$47.34M | $92.71B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.
Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
